Human Erythropoietin-alpha Recombinant
Catalog #
90257-A
$130
*
●
●
Purchase
Description
Recombinant human EPO-a is a glycosylated monomer protein consisting of 166 amino acids and, due to glycosylation migrates as an approximately 35 kDa protein under reducing conditions.
●
Synonyms
EPO, erythropoietin
Product Info
Storage and Usage
Citations
Species
Human
Host Species/Expression System
CHO
Purity
≥98% by SDS-PAGE and HPLC
Format
lyophilized protein
Formulation
Lyophilized from 0.2 µm filtered PBS solution, pH 7.0.
MW
35 kDa
Endotoxin Level
Endotoxin level was found to be < 0.1 ng/μg (1EU/μg), using the LAL gel clot method.
Biological Activity
Determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1, activity was found to be 0.8 x 105 IU/mg.
Genbank #
P01588
UniProt #
P01588
Background
EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary endothelial and interstitial cells of the kidney. Approximately 10-15% of the total amount of Epo comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of Epo is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behavior of Epo in vivo. Non- glycosylated Epo has an extremely short biological half life. It still binds to its receptor and may even have a higher specific activity in vitro.
References
J. Biol. Chem., Sep 2009, 284: 26988 - 26998.
Powered by Bioz
6405 Mira Mesa Blvd. Suite 100
San Diego, CA 92121
858-202-1401
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.